NCT00436722View on ClinicalTrials.gov

Induction Treatment Followed by Immunosuppression Withdrawal in Liver Transplantation: A Comparative Trial

PHASE2TerminatedINTERVENTIONAL

Enrollment

72

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

July 31, 2009

Conditions

Liver Diseases

Interventions

DRUG

ATG (Fresenius Biotech)

ATG-Fresenius 9 mg/kg at induction

Trial Locations (1)

08036

Hospital Clinic Barcelona, University of Barcelona, Barcelona

Sponsors

Collaborators (1)

Astellas Pharma Inc

All Listed Sponsors

collaborator

Fresenius AG

INDUSTRY

collaborator

Astellas Pharma Inc

INDUSTRY

lead

Hospital Clinic of Barcelona

OTHER

NCT00436722 - Induction Treatment Followed by Immunosuppression Withdrawal in Liver Transplantation: A Comparative Trial | Biotech Hunter | Biotech Hunter